• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis.

作者信息

Guglielmelli Paola, Maccari Chiara, Sordi Benedetta, Balliu Manjola, Atanasio Alessandro, Mannarelli Carmela, Capecchi Giulio, Sestini Ilaria, Coltro Giacomo, Loscocco Giuseppe Gaetano, Rotunno Giada, Angori Eva, Borri Filippo C, Tefferi Ayalew, Vannucchi Alessandro M

机构信息

CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy.

Doctorate School GenOMec, University of Siena, Siena, Italy.

出版信息

Blood Cancer J. 2023 Jan 30;13(1):21. doi: 10.1038/s41408-023-00786-x.

DOI:10.1038/s41408-023-00786-x
PMID:36710362
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9884661/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b3/9884661/f9c29a93a6b1/41408_2023_786_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b3/9884661/f9c29a93a6b1/41408_2023_786_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b3/9884661/f9c29a93a6b1/41408_2023_786_Fig1_HTML.jpg

相似文献

1
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis.骨髓纤维化患者中CALR突变变异等位基因频率的表型相关性
Blood Cancer J. 2023 Jan 30;13(1):21. doi: 10.1038/s41408-023-00786-x.
2
CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.四种不同亚型骨髓增殖性肿瘤患者（原发性骨髓纤维化、原发性血小板增多症、真性红细胞增多症和无法分类的骨髓增殖性肿瘤）的CALR、JAK2和MPL突变谱
Am J Clin Pathol. 2015 May;143(5):635-44. doi: 10.1309/AJCPUAAC16LIWZMM.
3
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.伴有钙网蛋白突变的骨髓增殖性肿瘤的独特临床特征。
Haematologica. 2014 Jul;99(7):1184-90. doi: 10.3324/haematol.2014.107482. Epub 2014 Jun 3.
4
The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in -mutant essential thrombocythaemia and primary myelofibrosis.I 型/II 型突变的不同变异等位基因频率和 - 突变原发性骨髓纤维化和特发性血小板增多症中的不同分子图谱。
Hematology. 2022 Dec;27(1):902-908. doi: 10.1080/16078454.2022.2107888.
5
Searching for CALRity in myeloproliferative neoplasms.在骨髓增殖性肿瘤中探寻CALR的真相。
Am J Clin Pathol. 2015 May;143(5):617-9. doi: 10.1309/AJCPZFWDM4GDTCI8.
6
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.JAK2 或 CALR 突变状态定义了具有显著不同临床过程和结局的特发性血小板增多症亚型。
Blood. 2014 Mar 6;123(10):1544-51. doi: 10.1182/blood-2013-11-539098. Epub 2013 Dec 23.
7
Somatic mutations of calreticulin in myeloproliferative neoplasms.髓系增殖性肿瘤中的钙网织蛋白体细胞突变。
N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.
8
Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.印度BCR-ABL1阴性骨髓增殖性肿瘤的分子遗传学
Indian J Pathol Microbiol. 2018 Apr-Jun;61(2):209-213. doi: 10.4103/IJPM.IJPM_223_17.
9
Who to screen for calreticulin mutations? An audit of real-life practice and review of current evidence.哪些人应筛查钙网蛋白突变？对实际临床实践的审核及当前证据综述
Eur J Intern Med. 2017 May;40:e22-e23. doi: 10.1016/j.ejim.2017.01.020. Epub 2017 Jan 26.
10
Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations.中国原发性血小板增多症和无JAK2（V617F）或MPL突变的原发性骨髓纤维化患者中CALR突变的频率和等位基因负荷
Leuk Res. 2015 May;39(5):510-4. doi: 10.1016/j.leukres.2015.02.006. Epub 2015 Feb 19.

引用本文的文献

1
CALR-mutant myeloproliferative neoplasms: insights from next-generation sequencing.钙网蛋白（CALR）突变型骨髓增殖性肿瘤：来自新一代测序的见解
J Appl Genet. 2025 Feb 17. doi: 10.1007/s13353-025-00947-7.
2
Editorial: Biological and clinical implications of the mutational landscape in myeloproliferative neoplasms.社论：骨髓增殖性肿瘤中突变图谱的生物学和临床意义
Front Oncol. 2024 Jul 16;14:1454837. doi: 10.3389/fonc.2024.1454837. eCollection 2024.
3
Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision Medicine.

本文引用的文献

1
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis.多参数流式细胞术评分的整合提高了原发性骨髓纤维化标准模型提供的预后分层。
Am J Hematol. 2022 Jul;97(7):846-855. doi: 10.1002/ajh.26548. Epub 2022 Mar 31.
2
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera.ASXL1突变在原发性骨髓纤维化中具有预后意义，但在真性红细胞增多症或原发性血小板增多症后的骨髓纤维化中则不然。
Blood Adv. 2022 May 10;6(9):2927-2931. doi: 10.1182/bloodadvances.2021006350.
3
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis.
真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化的分子认识进展：迈向精准医学
Cancers (Basel). 2024 Apr 26;16(9):1679. doi: 10.3390/cancers16091679.
4
Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.骨髓纤维化的分子遗传学特征：对诊断、预后及治疗进展的意义
Cancers (Basel). 2024 Jan 25;16(3):514. doi: 10.3390/cancers16030514.
5
Type 1 CALR mutation allele frequency correlates with CD34/CXCR4 expression in myelofibrosis-type megakaryocyte dysplasia: A mechanism of disease progression?1型CALR突变等位基因频率与骨髓纤维化型巨核细胞发育异常中的CD34/CXCR4表达相关：疾病进展机制？
Blood Cancer J. 2024 Jan 23;14(1):18. doi: 10.1038/s41408-024-00991-2.
6
-negative myeloproliferative neoplasms in the era of next-generation sequencing.下一代测序时代的阴性骨髓增殖性肿瘤
Front Genet. 2023 Sep 8;14:1241912. doi: 10.3389/fgene.2023.1241912. eCollection 2023.
7
Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing.根据靶向二代测序的基因组分类，原发性和继发性骨髓纤维化患者的临床特征及预后
Cancers (Basel). 2023 Jul 31;15(15):3904. doi: 10.3390/cancers15153904.
8
Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.骨髓纤维化表型与临床表现、分子特征及治疗的关联
Cancers (Basel). 2023 Jun 24;15(13):3331. doi: 10.3390/cancers15133331.
9
Structural and Dynamic Differences between Calreticulin Mutants Associated with Essential Thrombocythemia.与原发性血小板增多症相关的钙网织蛋白突变体的结构和动态差异。
Biomolecules. 2023 Mar 10;13(3):509. doi: 10.3390/biom13030509.
JAK2V617F 等位基因变异频率>50%可识别出患有静脉血栓形成高风险的真性红细胞增多症患者。
Blood Cancer J. 2021 Dec 11;11(12):199. doi: 10.1038/s41408-021-00581-6.
4
Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms.整合分子信息于骨髓增殖性肿瘤患者的风险评估中。
Cells. 2021 Aug 2;10(8):1962. doi: 10.3390/cells10081962.
5
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.原发性血小板增多症纤维化进展的临床和分子预测因素：一项涉及 1607 例患者的多中心研究。
Am J Hematol. 2021 Nov 1;96(11):1472-1480. doi: 10.1002/ajh.26332. Epub 2021 Sep 6.
6
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.原发性骨髓纤维化：诊断、危险分层和治疗的 2021 年更新。
Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2.
7
Detection and characterization of homozygosity of mutated by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high mutation loads or with progressive disease.在具有高突变负荷或疾病进展的骨髓增殖性肿瘤病例中，通过杂合性拷贝中性缺失检测和鉴定突变的纯合性。
Haematologica. 2019 May;104(5):e187-e190. doi: 10.3324/haematol.2018.202952. Epub 2018 Nov 8.
8
Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency.骨髓纤维化患者中钙网织蛋白的纯合突变导致获得性髓过氧化物酶缺乏。
Blood. 2016 Jun 23;127(25):3253-9. doi: 10.1182/blood-2016-02-696310. Epub 2016 Mar 24.
9
A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm.非典型骨髓增殖性肿瘤中，BCR-ABL1之前出现的CALR突变。
N Engl J Med. 2015 Feb 12;372(7):688-90. doi: 10.1056/NEJMc1413718.
10
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.原发性骨髓纤维化中预后不良突变的数量和预后：一项对 797 例患者的国际研究。
Leukemia. 2014 Sep;28(9):1804-10. doi: 10.1038/leu.2014.76. Epub 2014 Feb 19.